Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the ARAMIS Trial on Darolutamide

2019 Genitourinary Cancers Symposium

Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses study findings on the efficacy and safety of darolutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 140).

Sumanta K. Pal, MD, on Clinical Cancer Advances: The 14th Annual Report

Sumanta K. Pal, MD, of City of Hope, who served as a Co-Executive Editor of the 2019 publication Clinical Cancer Advances, discusses progress made during the past ye...

Kidney Cancer

Immunotherapy

Rana R. McKay, MD, on Renal Cell Carcinoma: Results From a Trial on Atezolizumab and Bevacizumab

Rana R. McKay, MD, of the University of California, San Diego, discusses phase II study findings on atezolizumab and bevacizumab in non–clear cell renal cell carcinoma and cl...

Prostate Cancer

Symptom Management

Today In Oncology

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the ARAMIS Trial on Darolutamide

Related Videos

Sumanta K. Pal, MD, on Clinical Cancer Advances: The 14th Annual Report

Rana R. McKay, MD, on Renal Cell Carcinoma: Results From a Trial on Atezolizumab and Bevacizumab

Silke Gillessen, MD, on Prostate Cancer: Results From the REDUSE Trial on Denosumab

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

FDA Pipeline: Designations in Myeloma, Adenoid Cystic Carcinoma, and Kaposi Sarcoma, Plus ODAC Votes

Does Quitting Smoking Affect Risk of Bladder Cancer in Postmenopausal Women?

Rate of 'Textbook Outcomes' in Curative-Intent Resection of Intrahepatic Cholangiocarcinoma

Control Arm Quality in Randomized Oncology Trials Leading to FDA Approval

Impact of Establishment of Cancer Urgent Care Clinic on Emergency Department Visits